论文部分内容阅读
目的探讨孟鲁司特辅助治疗儿童喘息性支气管炎的临床疗效。方法将70例喘息性支气管炎患儿随机分为两组,每组各35例。两组都采用相同的抗感染、平喘、化痰等综合治疗,治疗组加用孟鲁司特口服,对比两组患儿治愈率及总有效率,观察患儿临床症状、体征消失时间,观察不良反应。结果治疗组治愈率和总有效率显著高于对照组(P<0.05);治疗组咳嗽、气喘、肺部喘鸣音消失时间,住院时间均少于对照组(P<0.05);治疗组在治疗过程中未发现与孟鲁司特相关的不良反应。结论孟鲁司特辅助治疗可有效改善喘息性支气管炎患儿临床症状,缩短病程,提高儿童喘息性支气管炎的疗效。
Objective To investigate the clinical efficacy of Montelukast in the treatment of children with asthmatic bronchitis. Methods 70 cases of asthmatic bronchitis were randomly divided into two groups, each group of 35 cases. Both groups adopted the same anti-infective, antiasthmatic, phlegm and other comprehensive treatment, the treatment group plus oral montelukast, compared the cure rate and total effective rate of two groups of children, observe the clinical symptoms, signs disappear time, Adverse reactions observed. Results The cure rate and total effective rate in the treatment group were significantly higher than those in the control group (P <0.05). The treatment group had less cough, wheezing, disappearance of pulmonary wheeze and hospital stay than the control group (P <0.05) No untoward reactions associated with montelukast were found during treatment. Conclusion Montelukast adjuvant therapy can effectively improve the clinical symptoms of asthmatic bronchitis, shorten the course of disease and improve asthmatic bronchitis in children.